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Abstract
Although complex diseases and traits are thought to have multifactorial genetic basis, the common methods in genome-
wide association analyses test each variant for association independent of the others. This computational simplification may
lead to reduced power to identify variants with small effect sizes and requires correcting for multiple hypothesis tests with
complex relationships. However, advances in computational methods and increase in computational resources are enabling
the computation of models that adhere more closely to the theory of multifactorial inheritance. Here, a Bayesian variable
selection and model averaging approach is formulated for searching for additive and dominant genetic effects. The
approach considers simultaneously all available variants for inclusion as predictors in a linear genotype-phenotype mapping
and averages over the uncertainty in the variable selection. This leads to naturally interpretable summary quantities on the
significances of the variants and their contribution to the genetic basis of the studied trait. We first characterize the behavior
of the approach in simulations. The results indicate a gain in the causal variant identification performance when additive
and dominant variation are simulated, with a negligible loss of power in purely additive case. An application to the analysis
of high- and low-density lipoprotein cholesterol levels in a dataset of 3895 Finns is then presented, demonstrating the
feasibility of the approach at the current scale of single-nucleotide polymorphism data. We describe a Markov chain Monte
Carlo algorithm for the computation and give suggestions on the specification of prior parameters using commonly
available prior information. An open-source software implementing the method is available at http://www.lce.hut.fi/
research/mm/bmagwa/ and https://github.com/to-mi/.
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Introduction
In recent years, numerous genome-wide association studies
(GWAS) have been successful in locating disease or trait associated
variations in the human genome (see, e.g., discussion by Lander
[1]). The analyses are usually conducted by interrogating the effect
of a single genetic variant at a time and setting a stringent
threshold for statistical significance to account for multiple
hypothesis testing. While computationally convenient with the
hundreds of thousands of variants often genotyped, the strategy is
suboptimal, leaving just below the statistical significance a ‘‘gray
area’’ of variants. The identified variants often account only for a
minor portion of the estimated heritability of complex traits [2].
Advances in approximate computation and the increasing
computational resources have facilitated the computation of
models that simultaneously consider all variants, with demonstra-
tively better performance for identifying trait associated variants at
least in simulations [3–6]. These methods adhere more closely to
the hypothesis of multiple variants affecting complex traits and
gain power from accounting for the multiple genetic effects
simultaneously. Moreover, some formulations of the problem,
specifically Bayesian variable selection and model averaging
(BMA), naturally provide estimates of the uncertainties in the
quantities of interest and allow for inferences beyond the marginal
significance of single variants. For example, Wilson et al. [5]
compute probabilities of association for regions of the genome
(e.g., genes), and Guan and Stephens [6] estimate the heritabilities
of traits (to the extent explained by the available genetic data). The
flexibility of the approach also allows for extensions to simulta-
neous analysis of multiple traits [7,8] and interactions [9,10].
Here, we study the potential of BMA in genome-wide modeling
of additive and dominant genetic variation. Although, in principle,
a simple extension of the additive genetic model, it is computa-
tionally burdensome and can lead to a reduction in the power of
identifying associated loci. We focus our analysis on a formulation
of genetic effects, where each variant can contribute either an
additive or an additive and a heterozygosity term. This
formulation allows for the modeling of (complete and incomplete)
dominance. As baseline models, we use a purely additive
formulation and a pseudo-SNP approach, where the number of
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variants is naively doubled by introducing an additional pseudo
variant with heterozygous coding for each genetic variant.
Rationale for the latter is that it allows for the modeling of
dominance and any software handling the basic additive
formulation could be used for the analysis. The behavior of these
models is studied in simulations based on real single-nucleotide
polymorphism (SNP) data and the results are compared against
conventional single-SNP analysis. An application to the analysis of
the genetic basis of variation in key lipid metabolism components
in the circulation, high-density (HDL-C) and low-density lipopro-
tein cholesterol (LDL-C), is then presented. The dataset consists of
3895 Finnish individuals with (imputed) genotypes available on
over one million SNPs.
The simultaneous identification of trait associated (causal or
correlated to causal) variants is facilitated by modeling the
genotype-phenotype mapping as a sparse multiple linear regres-
sion, where only a small proportion of the variants is expected to
have non-zero effects. Specifically, our formulation corresponds to
a type of spike-and-slab prior [11,12], which is a popular choice in
Bayesian variable selection with a large number of variables. In the
context of GWAS, this allows us to naturally incorporate prior
knowledge on the expected number of associated loci and effect
sizes or heritability, which are nowadays often available from
previous studies for common traits. To learn which of the
hundreds of thousands or millions of variants have non-zero effects
(i.e., are associated to the trait) is a great computational challenge.
To this end, such a prior structure for the linear model is assumed,
which allows analytic integration over several of its parameters.
Sampling is then utilized to identify the associated variants.
Specifically, we present a Markov chain Monte Carlo (MCMC)
algorithm, which samples from posterior distribution of the model
space by proposing additions, removals and swaps of the variants
that are allowed to have non-zero effects. The sampling effort is
focused more on variants showing some effect on the trait by
adapting the proposal distribution of additions to the marginal
association probabilities during an initial phase of the sampling.
Sampling algorithms with similar rationales have been utilized at
least by Clyde et al. [13], Guan and Stephens [6] and Nott and
Kohn [14].
An excellent general discussion on Bayesian variable selection in
GWAS is provided by Guan and Stephens [6]. Our primary
contribution here is to investigate extending this approach to
simultaneously model both additive and dominant genetic effects.
Other authors (e.g., [5,9,15]) have previously studied BMA
models, which include terms for dominance variation, but they
have not explicitly focused on this and their prior for the effect
types have been different and the scale of datasets smaller. Our
formulation seems robust with regard to the potential loss of power
in such extensions of model space, and may lead to improved
estimates of key quantities such as the heritability of a trait. These
results may be seen as demonstrations of the benefits of explicitly
accounting for the multifactorial genetic basis of complex traits
within hierarchical modeling.
Methods
Model
Let yi, i~1, . . . ,n, be measurements of a continuous phenotype
of interest for n individuals, and xi~½xi1 . . . ximT , i~1, . . . ,n, be
vectors of the values for m (usually m&n) genetic variants (here,
the numbers of minor alleles of SNPs) for each individual. The
trait is then modeled as a linear combination of the variants and
other covariates ei:
yi~e
T
i az
Xm
j~1
cj ftj (xij)bjzEi, ð1Þ
where a and bj are the regression coefficients and Ei is the residual.
The binary variables cj indicate which effects are included in the
model. The function ftj (xij) describes the type of the effect of SNP
j. In the case of additive genetic model, this is fA(xij)~xij .
Types of genetic effects. Let M and m be the major and
minor alleles at a SNP. The following types of genetic effects may
be considered:
N Additive (A) with 0, 1, 2 coding for the genotypes MM, Mm/
mM, mm.
N Heterozygous (or dominance deviation; H) with 0, 1, 0 coding
for MM, Mm/mM, mm.
N Dominant (with respect to the minor allele; D) with 0, 1, 1
coding for MM, Mm/mM, mm.
N Recessive (with respect to the minor allele; R) with 0, 0, 1
coding for MM, Mm/mM, mm.
The model indicator tj obtains values in f0,A,D,R,H,AHg
with the functions fA(:), fH(:), fD(:), fR(:) formed according to the
above codings and fAH(:)~½fA(:) fH(:) (a two-element vector of
the A and H functions). The effect type 0 is fixed for cj~0, where
the coding does not matter.
The attention will be restricted to models, which allow 1)
additive effects (referred to as BMA A), 2) additive or additive and
heterozygous effects (BMA A/AH) and 3) additive effects with
pseudo variants (BMA pseudo); see Table 1. The first model is
commonly used in genome-wide association studies, but it does not
model dominance. The second model is our primary interest. Note
that the fully dominant (D) and recessive (R) effects are special
cases of AH with bAHj ~½1 1bDj =2 and bAHj ~½1{1bRj =2,
respectively. The third model is handled identically to BMA A,
but the number of variants is doubled by adding a pseudo variant
with heterozygous coding per each original variant.
Table 1 lists the model space sizes. The model spaces are
enlarged by factors of (3=2)m and 2m for BMA A/AH and pseudo,
respectively, compared to BMA A.
Model space prior. The variable selection is facilitated by
placing a prior distribution on the vector c~½c1 . . . cm, which
controls the inclusion of variants into the model. A common
choice is (with the notation for probability distributions following
Gelman et al. [16])
p(cDv)~P
j
Bernoulli(cj Dv)
Table 1. Bayesian model averaging formulations and genetic
effects.
Model Allowed effects Model space size
BMA A 0, A 2m
BMA A/AH 0, A, AH 3m
BMA pseudo 0, A 22m
Model space refers to the possible combinations of ª and t. m is the number of
variants. Pseudo refers to including a pseudo-SNP with heterozygosity coding
for each SNP.
doi:10.1371/journal.pone.0029115.t001
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p(v)~Beta(vDav,bv),
where v is the probability of including a variant in the model and
can be integrated out analytically. The prior serves a similar role to
the classical multiple hypothesis testing correction [17]. Kohn et
al. [18] give formulae for determining the hyperparameters av and
bv by considering the expected number of associated variables and
its variance. This is natural also in the present application as there
often are available some broad estimates of the number of causal
variants from previous studies.
A functionally similar prior can be used for the effect types t
given c:
p(tDw,c)~ P
j:cj~1
Categorical(tj Dw) ð2Þ
p(w)~Dirichlet(wDb(1)w ,:::,b
(k)
w ),
where w is a vector of the probabilities of the different genetic
effects. This also allows integrating w out analytically and provides
a further multiple testing adjustment. The parameters b
(i)
w can be
thought of as prior samples of the different types of effects. For
example, setting them to large equal values would effectively
correspond to giving probability
1
k
for each effect type.
Priors of the linear model. In matrix notation, the
regression model in Equation 1 can be written as
y~EazXªbªze ,
where y~½y1 ::: ynT , E is the design matrix of fixed covariates,
Xc is the design matrix of the variants for which cj=0 formed
according to the above discussion of effect types, bc is the vector of
the corresponding regression coefficients and e~½E1 ::: EnT .
The distribution of the residual is assumed normal
p(e)~N(e D0,s2I)
and conjugate prior distributions are placed on s2, a and bc, with
b following a spike-and-slab formulation [11,12]:
p(s2)~Inv{x2(s2Dns2 ,s
2
s2
)
p(al Ds2)~N(al D0,s2s2al )
p(bj Ds
2,t2,tj ,cj~1)~N(bj D0,s
2t2tj
)
p(bj Dcj~0)~d0,
where d0 is the Dirac delta function at zero (the inclusion of cjs in
the Equation 1 was redundant). Note that t2tj
are allowed to be
different depending on the effect type (e.g., for BMA A/AH we
have t2~½t2A t2H ; here, for a variant with cj~1 and tj~AH, bj
has actually two components with prior variances s2t2A and s
2t2H ).
The structure allows marginalizing over b and s2 analytically
given the other parameters. A popular alternative prior for bc is
the g-prior [19]. However, some of its properties seem undesirable
for application in GWAS: in particular, the assumption about the
correlation structure of the genetic effects (see [6]) and the implied
smaller shrinkage for the effects of rare variants (see [20] for a non-
GWAS specific discussion).
The prior for the variable selection coefficients are given the
semi-conjugate form
p(t2t )~Inv{x
2(t2t Dnt2t
,s2
t2t
),
which allows convenient sampling of t2 given the other
parameters. Guan and Stephens [6] use an alternative formula-
tion, where the prior for t2 is indirectly induced through a prior on
heritability and depends on c. We use similar reasoning to guide
the specification of hyperparameters (see below), but do not
explicitly tie t2 and c. The question whether the parameters
should be tied in the prior relates to whether one is more confident
in specifying prior information on the effect sizes or on how much
of the phenotypic variance the available genetic data could overall
explain.
Finally, to account for missing data a categorical prior is placed
on an element of X :
p(xij DXobs)~Categorical(xij Dh0ij ,h
1
ij ,h
2
ij),
where Xobs refers to the observed genotype data and h
k
ij is the prior
probability of the genotype k. Thus, for observed data with
genotype K , hKij is set to one and other h
k
ij to zero and for missing
data, hkijs are set to the marginal distribution of the genotypes for
the corresponding SNP. In general, the hkijs could be set, for
example, to the genotype probabilities from imputation algo-
rithms.
Elicitation of ns2 , s
2
s2
, nt2 and s
2
t2
. Often estimates of the
heritability of the trait are available from published genome-wide
association studies or from some other sources (of course, often the
studied data cannot be assumed to exhaustively cover all genetic
variation, but is restricted to, for example, SNPs). This prior
knowledge can be used to guide the setting of the hyperparameters
of the variance distributions in the model.
First, note that the proportion of variance explained by the
linear model
R2~
var½xb
var½y ~
var½y{s2
var½y :
Placing a distribution with density p
s2
(s2) (here Inv{x2) on s2
induces a distribution for R2, which given the population variance
var½y has density p
R2
(R2)~p
s2
((1{R2)var½y)var½y. We suggest
setting the hyperparameters ns2 and s
2
s2
by inspecting the implied
prior on R2. While the prior can have mass on negative values of
R2, the likelihood of the linear model will usually be concentrated
on the positive values or around zero if there is no explanatory
power in the model. The connection to heritability estimates can
be made by assuming independent contributions of genetic
(heritability H2) and environmental (known covariates; R2e ) effects.
Then R2~H2zR2e and, for example, an empirical estimate of R
2
e
from simple linear regression may be used. One possibility is then
to fix the mode of prior to the expected R2 and choose the other
Genome-Wide Search of Additive & Dominant Effects
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degree of freedom so that the prior is relatively flat around
plausible values of R2.
Similar derivation can be made for a single effect with
heritability contribution H2j :
H2j~
var½xjbj 
var½y ~
(E½xj 2zvar½xj )var½bj 
var½y ~
E½xj 2zvar½xj 
var½y s
2t2t~
(E½xj 2zvar½xj )(1{R2)t2t ,
where xj and bj are assumed independent. Now, given R
2, E½xj 
and var½xj  setting a distribution for t2t induces a distribution for
H2j . To solve for the hyperparameters nt2t
and s2
t2t
, one can consider
setting R2 to its expected value and set the expectation and variance
of H2j according to prior knowledge (e.g., coarsely setting
E½H2j ~H2=q with q being the expected number of causal
variants). The support of the prior may then be checked over a
range of plausible R2 values. We have used the sample estimates of
var½y, E½xj  and var½xj  (specifically, mean over all variants and
mean of the variances of the variants) in our experiments.
Covariates e. A constant term of ones is included to account
for non-zero mean of the trait. An improper prior is placed for the
corresponding regression coefficient: p(a0)~N(a0D0,s2s2a0 ), where
s2a0??. While this makes the marginal likelihood of the linear
model (Text S1, step 3) tend to zero, the posterior distribution of c
and the Bayes factors required in the computation have proper
limits (see Protocol S1 in the supplementary materials of [15]). For
other fixed covariates, the variance parameters s2al are set to
suitable (fixed) values.
Computation
Markov chain Monte Carlo (MCMC) sampling is used to
generate samples from the posterior distribution of the model
parameters. The sampling of c and t is performed with
Metropolis-Hastings algorithm [21,22], where local updates are
proposed as explained below. Gibbs sampling [23] scheme is used
to update the parameters sequentially. The sampling consists of
iterating five steps (see Text S1 for brief derivations of the
sampling distributions):
1. Sample xij given X{ij , a, b, t
2, s2, c, t, y for all missing data
from categorical distributions. Sampling of missing genotypes
in variants that are not included in the model (cj~0) can be
disregarded as they do not affect the sampling of the other
parameters. An exception is such a variant that is considered
for addition to the model in the third step.
2. Sample t2 given X , a, b, s2, c, t, y from (independent) Inv{x2
distributions.
3. Sample c, t given X , t2, y by a local Metropolis-Hastings move
(see below). Note that a, b and s2 can be integrated out
analytically at this step.
4. Sample s2 given X , t2, c, t, y from Inv{x2 distribution.
5. Sample a, b given X , t2, s2, c, t, y from multivariate normal
distribution.
Note that the steps 3–5 can be seen as a draw from a block
distribution p(c,t,s2,a,bDX,t2,y), which is decomposed into three
steps. Steps 1 and 2 sample from full conditionals. While the local
moves at step 3 require only updates of complexity O(M2) to the
Cholesky decomposition used in the regression, step 1 requires the
computation of a full Cholesky decomposition of complexityO(M3),
where M is the number of variables with cj~1. As c is of primary
interest and the local updates lead to large autocorrelations, step 3 is
repeated a number of times (here 10) before moving on.
Local updates to c, t. After proposing an update of c, t the
move is accepted or rejected according to the Metropolis-Hastings
acceptance probability u:
u~min
p((ª,t)newDt2,y,X)
p((ª,t)oldDt2,y,X)
q((ª,t)oldD(ª,t)new)
q((ª,t)newD(ª,t)old)
,1
( )
, ð3Þ
where q is the proposal distribution, which is here decomposed
into three steps: 1) update type, 2) variant and 3) effect type.
Four types of updates are considered:
1. addition of a variant to the model,
2. removal of a variant from the model,
3. switch of two variants (combination of the two above),
4. switch of effect type for a variant,
with probabilities 0.4, 0.4, 0.1 and 0.1. For updates 2 and 4, the
variant is chosen randomly among the variants in the model
(disregarding the effect type). Update 3 is formed as a composition of
updates 1 and 2. The proposal distributions for additions and
selection of effect types are formed adaptively during an initial
sampling period as explained below, after which they are fixed.
Samples from the adaptive phase are not used for posterior inference.
The proposal distribution for additions is formed according to
the marginal association probabilities of the variants (pj ), which
are updated during an initial sampling phase. The values are
initialized to the single-SNP association probabilities and updated
according to the Rao-Blackwellized probabilities (see below;
computed every 1000th iteration). Specifically, the proposal
probability for addition of jth variant is ZpTj , where Z normalizes
the distribution over all j and T[½0,1 is a prespecified constant,
which can be used to flatten the distribution (e.g., T~0 leads to
uniform proposals, we have used T~0:5). The proposal
distributions for the effect types are formed similarly, but the
probabilities for effect types are calculated for each variant
independently. The rationale of this proposal strategy is to guide
the sampling to those SNPs that are more likely to be significant
and thus, to increase the acceptance and convergence rates of the
sampler in cases with a very large number of variables, with most
variables expected to be insignificant.
Posterior association probabilities. Guan and Stephens
[6] propose using Rao-Blackwellized estimates of posterior
association probabilities to reduce sampling variance relative to
MCMC frequency estimates. Following their derivations, the
estimate of the marginal association probability is computed as a
mean over the MCMC samples:
pj~Pr (cj~1Dy)~
1
Ns
XNs
s~1
Pr (cj~1Dy,h
(s)
{j),
where Ns is the number of samples and h~(ª,t,b,a,t2,X) ({j
indicates the removal of parameters specific to variable j). Here,
the probabilities of effect types (t) are also tracked by computing
Pr (tj Dcj~1,y) in a similar fashion. Both of these can be computed
by computing the odds
Pr (cj~1,tj Dy,h
(s)
{j)
Pr (cj~0,tj Dy,h
(s)
{j)
~
Pr (cj~1,tj Dª
(s)
{j ,t
(s)
{j)
Pr (cj~0,tj Dª
(s)
{j ,t
(s)
{j)
Pr (yDcj~1,tj ,h
(s)
{j)
Pr (yDcj~0,tj ,h
(s)
{j)
Genome-Wide Search of Additive & Dominant Effects
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29115
for each value of tj . The Bayes factors are fast to compute as they
are linear regressions of two or three variables (constant and one or
two terms for the variant) [6].
Single-SNP analysis and the Bayesian model averaging (BMA)
approach behave differently in the estimation of the marginal
significances of variants in regions with high linkage disequilibrium
(LD): while single-SNP methods report similar significances for the
variants in the region, BMA tends to dilute the posterior
probability mass among the variants, since only one of them is
needed in the model. It is then sensible to compute the posterior
probabilities for regions of the genome. Often the actual causal
variants cannot anyway be assumed to be among those genotyped.
Unfortunately, the Rao-Blackwellization approach is not feasible
for this, although summing over the association probabilities
within a region can be used as an estimate of the number of
associated variants within the region [6]. However, the association
probabilities over large regions could be expected to suffer less
from sampling variance than over single variants. Thus, frequency
estimates from the MCMC chains are used instead. With
V~fv1,:::,vrg defining the indices of the variants within the
region
pV~Pr (Vassociated)~
1
Ns
XNs
s~1
I(fvj[V : c(s)vj~1g=0=),
where I(x)~1 if x is true and 0 otherwise. Note that the prior
probability of association of V depends on the size r of the region.
For moderate sizes the prior probabilities are small. It is also
possible to compute Bayes factors comparing the hypothesis of
association of a region to no association [5]. The probabilities of
effect types for a region are computed by frequency estimates over
MCMC samples, in which at least one variant within the region is
included in the model.
Ethics statement
Human data was not collected primarily for this article and was
analyzed here anonymously. Primary collection has followed
appropriate ethics guidelines.
Results
Simulations
Simulations were used to characterize the behavior of the
models and to validate the approach against a single-SNP
approach implemented in the popular software PLINK (version
1.07; see Text S2 for the used analysis options) [24]. To account
for the linkage disequilibrium structure of the genome, real
genotype data of chromosome 1 from 2002 individuals was used in
the simulations. This consisted of 85,331 SNPs after imputation
and quality control. Quantitative traits were simulated according
to a linear model with the following steps: 30 causal variants were
selected randomly among the SNPs, effect types were either all set
to additive (sim A) or selected randomly from additive, dominant
or recessive (sim A/D/R). The effect sizes were generated from a
double exponential distribution and normally distributed noise was
added to achieve a preset level of heritability H2 (0.2 or 0.5). Forty
datasets were simulated with each parameter configuration.
Weakly informative prior distributions were used for the
Bayesian model averaging (BMA). Specifically, correct values
were used to set means and modes, but the distributions were
given large variances (E½q~30, var½q~302, where q is the
number of included variants, ns2~1, mode of s
2 was set according
to H2, nt2~3, E½H2i ~H2=30, bw~1). Two chains of length two
million samples were run for each dataset and model. Second
halves of the chains were thinned by taking every 100th sample
and used for posterior inference.
Causal variant identification performance. To make
BMA and PLINK better comparable, the genetic map of
chromosome 1 from HapMap (phase 2, release 22) [25] was
used to divide the SNPs into regions with boundaries at loci, where
adjacent SNPs were more than 0.01 cM apart. This resulted into
3776 regions. Similar results were obtained by using a lower
threshold (0.005 cM; 6421 regions; Figure S1) or by dividing the
SNPs into LD blocks with an algorithm in Haploview software
[26] (Figure S2). For single-SNP results, minimum of the p-values
within a region was taken. For BMA, region-wise marginal
posterior probabilities were computed as frequency estimates from
the MCMC chains.
Figure 1 shows the true positive rates as a function of the false
positive rates for the approaches, with the forty replicate
simulations combined (similar to Guan and Stephens [6]). BMA
has clearly better performance in these simulations than
conventional single-SNP analysis (PLINK and single-SNP poste-
rior probabilities gave similar results; Figure S3). The difference is
larger with the higher heritability. This is plausible as there is less
residual variation available for producing chance associations in
the multivariate linear models after the strongest associations have
been accounted for. When only additive effects (sim A) are
simulated, there is little difference between BMA A and BMA A/
AH, but BMA pseudo performs slightly worse. Single-SNP analysis
with AH model suffers a small drop in performance compared to
only A. With additive, dominant and recessive effects (sim A/D/R)
BMA A/AH shows some improvement over BMA A and pseudo.
The improvement is larger with higher heritability.
Effect type identification. Effect type identification
accuracies for causal variants were computed on the region level
weighted with posterior association probabilities pi:
accuracy~
1P
j pj
X
j
pjI(true effect type at j~
maximum a posteriori effect type at j),
ð4Þ
where I is an indicator function with value 1 if the argument is
true and 0 otherwise. Simulated D and R effects were classified as
AH. The effect type of a SNP in BMA pseudo was classified as AH
if the pseudo term was present in the model and A otherwise. The
motivation for the weighting scheme is that only the effect types of
variants with high posterior association probability are of interest.
Table 2 shows the accuracies as an average over the replicate
simulations. The results are mixed. Both BMA A/AH and pseudo
have high accuracies, when only additive effects are simulated,
especially with the higher heritability and clearly have some ability
to identify dominant and recessive effects, although the accuracies
are well below 80% even in the higher heritability simulations.
Looking more closely at the types of errors of BMA A/AH, there is
little difference in percentages of confusing A to AH and AH to A
(both are 30% with H2~0:2 and 25% with H2~0:5).
Heritability and model sizes. The Bayesian model
averaging approach facilitates inferences on heritability
(calculated as the proportion of variance explained by the
genetic effects from the MCMC samples) and the number of
causal variants. Figure 2 shows 95% central posterior intervals for
heritability in the simulated datasets. With only additive effects, all
BMA formulations cover the true value in most replicate
simulations. Lower heritability leads to longer intervals as there
is generally more uncertainty about the model parameters. With
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additive, dominant and recessive effects (sim A/D/R), BMA A is
biased to lower than true values, especially with the higher
heritability, while BMA A/AH and pseudo have good coverage of
the true values.
The model size distributions are summarized with 95% central
posterior intervals in Figure 3. Only distinct SNPs are counted in
BMA pseudo (i.e., having both A and H terms of the same SNP
count only as one). Three trends are visible. First, lower heritability
leads to larger uncertainty in the number of variants to include.
Second, the model sizes are generally biased to smaller than true
values. This may be explained by the discrepancy in the prior
(normal) and the simulation (double exponential) distributions for
the effect sizes. It is probable that many of the simulated effects are
small, falling below the implicit identification threshold, and do
not contribute much to heritability. Third, BMA pseudo produces
on average larger models than BMA A or A/AH and has wider
posterior intervals.
HDL-C and LDL-C analysis
The Bayesian model averaging (BMA) approach was then
applied to real data. BMA A (additive) and A/AH (additive or
additive and heterozygous terms) models were used.
Data and prior parameters. Data were available from 3895
Finnish individuals from two studies. 2002 of the individuals were
from a metabolic syndrome case-control sample [27] and 1893
were controls of another study (a subgroup of FINRISK study
[28]). Data on high-density lipoprotein blood cholesterol (HDL-C)
levels was available for all individuals and on low-density
lipoprotein cholesterol (LDL-C) for 3822 individuals. LDL-C
values were estimated with the Friedewald formula [29]. The
genotype data were imputed with IMPUTE2 program using
HapMap 3 reference samples with an additional Finnish founder
population reference [30]. Maximum a posteriori genotypes were
used from the imputation, which allows for simple handling of
multiple effect types with memory-efficient implementation
(posterior mean genotypes have been recommended as an
approximation to sampling over the imputation uncertainty, see
[31]). Missing values in the genotyped SNPs were not imputed.
After imputation, 1,051,811 SNPs passed quality control
(imputation certainty w0:95, Hardy-Weinberg equilibrium
p§0:0001, minor allele frequency §0:02 and missingness
ƒ0:05; adjacent SNPs with identical genotypes were removed)
and were available for both datasets. Study indicator, metabolic
syndrome case-control indicator, age, age2, sex, body-mass index,
Figure 1. Causal variant identification performance in simulations. True positive rate as a function of false positive rate in simulations with
all forty replicate datasets combined within each configuration (i.e., each dataset has the same cutoff for calling positives and the number of true and
false positives are summed over the datasets).
doi:10.1371/journal.pone.0029115.g001
Table 2. Effect type identification accuracy in simulations
(weighted with posterior association probability).
sim. effects sim. H2 BMA A/AH BMA pseudo
sim A 0.2 86% 94%
sim A/D/R 0.2 70% 66%
sim A 0.5 98% 97%
sim A/D/R 0.5 75% 76%
doi:10.1371/journal.pone.0029115.t002
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lipid lowering medication together with coarse indicators from
questionnaires on education, physical activity and alcohol use were
included as covariates. Missing covariates were imputed with
regression models based on the other covariates using mi-package
in R [32]. Ten principal components with the largest eigenvalues
were estimated [33] from the genotyped SNPs (i.e., excluding
imputed) and included as covariates to account for population
stratification.
Location parameters of the prior distributions were specified
based on a recently published large meta-analysis investigating
blood concentrations of lipids [34]. Prior variances were set to
relatively large. For HDL-C: E½q~47, which is the number of
identified SNPs in the meta-analysis, var½q~402, ns2~1, mode of
s2 was set according to heritability estimate from the meta-analysis
H2~0:12 and empirical R2e~0:29 for the covariates, nt2~4,
E½H2i ~H2=47, bw~1. For LDL-C: E½q~37, var½q~302,
ns2~1, H
2~0:12 and empirical R2e~0:18 for the covariates,
nt2~4, E½H2i ~H2=37, bw~1. Three MCMC chains of length six
million iterations were run for each model and dataset and thinned
by taking every 100th sample. Only the second halves were used
for posterior inference. Convergence was assessed by visually
comparing the three chains and by computing the potential scale
reduction factor [16] for shared continuous parameters. These did
not indicate any problems. Comparing the marginal posterior
association probabilities of SNPs between chains shows some
problems in mixing between correlated variants (Figure S4).
However, region-wise probabilities do not seem to suffer from this
(Figure S4).
Figure 2. BMA 95% central posterior intervals for heritability in simulations. Each of the forty replicate datasets within all configurations
are shown for BMA A, A/AH and A/D/R. The true value is indicated with a vertical line.
doi:10.1371/journal.pone.0029115.g002
Figure 3. BMA 95% central posterior intervals for the number of causal variants in simulations. Each of the forty replicate datasets
within all configurations are shown for BMA A, A/AH and A/D/R. The true value is indicated with a vertical line.
doi:10.1371/journal.pone.0029115.g003
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Posterior association probabilities. The posterior
association probabilities were computed for regions of the
genome using HapMap genetic maps (phase 2, release 22) [25].
The variants were assigned into regions with boundaries at loci,
where adjacent SNPs in the genetic map were more than 0.01 cM
apart. The posterior probabilities for the resulting 46,172 regions
are shown in Figure 4 for BMA A/AH. BMA A gives very similar
results for both traits (Figure 5) and is not shown. Ten randomly
permuted versions of the HDL-C dataset were analyzed for
reference, the results of which show no region-wise posterior
association probabilities over 0.5 (Figure S5).
For HDL-C, there are seven regions with posterior association
probability over half, five of which have been identified previously
[34]. Computing estimates for the number of associated loci in each
region indicates that the region with probability near one in
chromosome 16 harbors two associations (Figure S6). The SNPs
showing association in this region are located immediately upstream
or in the CETP gene. The two associations (one of which is in region
not reported by Teslovich [34]) in chromosome 15 are in or
upstream of LIPC gene. The previously unreported (to our
knowledge) putative association on chromosome 5 is about 14 kbp
upstream of CAST gene and is suspect to being a false positive.
For LDL-C, there are five regions with posterior association
probability over half, four of which are in regions, where LDL-C
associated SNPs have been found previously in the large meta-analysis
study [34]. Closer inspection shows that the fifth association, in
chromosome 1, is located in gene PCSK9, in and near which
associations to LDL-C have also been previously reported. The
estimate for the number of associations in this region is 1.6 (Figure S6)
with some weaker signals in the near-by USP24 gene. The second
associated region in chromosome 19 has an estimated number of
associations of 1.4. This region is located around TOMM40, APOE
and APOC1 genes, variants in which have been previously found
associated to cholesterol levels (the latter two code for apolipoproteins).
Figure 4 shows regions, where the AH effect is more probable
than A with hollow circles (otherwise filled). There are no such
regions for HDL-C showing even moderate signal for association
and only few for LDL-C. The strongest region, with posterior
association probability of 0.41, is in chromosome 11. SNPs in this
region showing association are located in LDLRAD3 gene.
Figure 5 shows also a comparison of the significance values from
PLINK A and AH for HDL-C highlighting a clear qualitative
difference in the behavior of BMA and single-SNP analysis.
Moreover, only three of the seven regions with posterior
association probability over half for HDL-C reach genome-wide
significance level (here pv10{8) in the single-SNP analysis (Figure
S7). For LDL-C, all of the five regions reach this level (except for
one close call in AH analysis; Figure S7). PLINK AH indicates five
SNPs for HDL-C with borderline genome-wide significance that
are not picked up by only A model or the BMA models. These
SNPs show clear recessive association patterns, but each with only
a single observation having two minor alleles. It seems that testing
the regression coefficients for statistical significance is not a very
robust approach with additive and heterozygosity terms.
Heritability and the number of associated variants. Her-
itability samples were obtained from the MCMC as the proportion of
(all phenotypic) variance explained by the included genetic effects
(Figure 6). The median heritabilities for HDL-C were 0.08 with both
methods and for LDL-C 0.08 and 0.09 with BMA A and A/AH,
respectively. The histograms for HDL-C are nearly identical and are
Figure 4. BMA A/AH posterior association probabilities for HDL-C and LDL-C. The SNPs have been divided into 46,172 regions based on
HapMap genetic map. Regions, where AH effect has higher probability than A are shown as hollow circles, others as filled. Crosses indicate loci
identified in a large meta-analysis [34]. Two close-by regions on chromosome 15 have probabilities near one for HDL-C, but only one can be seen due
to overlapping markers.
doi:10.1371/journal.pone.0029115.g004
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much narrower than those of LDL-C. LDL-C with BMA A/AH has
slightly wider distribution and larger mean than with BMA A. Similar
observations can be made for the number of included variants in the
models: the medians [with 95% central posterior intervals] are 32
½14; 71 and 29 ½13; 66 for HDL-C with BMA A and A/AH, and 42
½15; 115 and 44 ½15; 120 for LDL-C.
Discussion
Our results demonstrate that Bayesian variable selection and
model averaging (BMA) in searching for additive and dominant
genetic effects is feasible on genome-wide scale and has several
potential benefits over single-SNP analysis. The primary interest in
genome-wide association studies (GWAS) often lies in locating
causal variants (or variants linked to them), which may provide
insight into the underlying biology of the phenotype, indicate new
therapeutic targets for diseases and enable personalized risk
analytics [1]. As complex traits are thought to involve multiple
genetic effects, it is not surprising that the simultaneous analysis of
all available variants has been found to increase the identification
accuracy (at least in simulations) [3–6]. Our simulation study
supports this (Figure 1). Our results also imply that if genetic
dominance is present, allowing heterozygosity (AH) terms in the
BMA models can provide a further increase in the accuracy.
Moreover, in the analysis of HDL-C blood concentrations in 3985
Finns, BMA highlighted regions with previously reported
associations, which did not reach genome-wide significance in
the single-SNP analysis of this dataset. Further analysis of the
implied associations is out of the scope of our article.
Notably, even if only additive effects were simulated, there was
virtually no decrease in the identification accuracy from allowing
AH terms. This behavior can (at least partly) be explained by
allowing the data to provide information on the relative numbers
of the different types of effects t through their prior (Equation 2).
The effect of the prior is also clearly visible when comparing the
results of BMA and single-SNP analysis for the HDL-C data in
Figure 5. In the current form, the model becomes more and more
conservative against other effect types as more and more variants
with a single effect type are added. In situations where this is
undesirable, the prior could be fixed to uniform over the effect
types or its strength relative to the number of included variants
could be controlled (by allowing w to depend on c). However, this
behavior is a demonstration of the key feature of ‘‘sharing of
strength’’ in hierarchical modeling, and highlights one of many
potential benefits in the simultaneous analysis of all variants.
We also compared the BMA A/AH approach to a pseudo-SNP
approach, which doubles the number of variants by introducing an
additional pseudo SNP with heterozygosity coding for each
original SNP. This allows simple modeling of dominance without
requiring any special implementation handling different effect
types. However, our simulations indicate that an explicit model for
the dominance variation may increase the performance of
identifying associations. Moreover, the prior specification of model
size and effect types are more natural when an explicit model is
used. The performance for the identification of the types of effects
had mixed results in our simulations.
The BMA approach facilitates posterior inference on heritabil-
ity based on genotype data of unrelated individuals as studied by
Guan and Stephens [6]. Here it is useful to note the difference
between narrow- and broad-sense heritability. The former is
defined as the proportion of phenotypic variance explained by
additive genetic effects, while the latter includes also non-additive
components (e.g., dominance). Hill et al. [35] argue based on
literature and theoretical considerations that the additive compo-
nent is expected to account for most of the genetic variance of
complex traits. Our simulation and real data results seem to be in
line with this (disregarding the possibility of gene-gene and gene-
environment interactions). Although in the second set of our
simulations two thirds of the effects are either dominant or
recessive, models with only additive effects, while being clearly
Figure 5. Comparison of region-wise posterior association probabilities for BMA A and A/AH. Similar plot for PLINK{ log10 p{values is
included for reference (region-wise maximum values; one point with values w12 is shown with a cross).
doi:10.1371/journal.pone.0029115.g005
Figure 6. Posterior distributions of heritability for HDL-C and
LDL-C. Median values are 0.08 for all except for LDL-C BMA A/AH,
which has a median of 0.09.
doi:10.1371/journal.pone.0029115.g006
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biased downwards, seem to capture a large part of the overall
heritability (Figure 2). For HDL-C and LDL-C, a large meta-
analysis study reported that about 12% of the total variances of
each were explained by the identified SNPs, which is only around
25 to 30% of the genetic variances of the traits [34], highlighting
the general observation that associations in SNP data often
account for a small part of total heritability [2]. The cited values
are at the upper ends of our posterior distributions (Figure 6). Our
results imply no dominance component for HDL-C and a
possibility of a small dominance component for LDL-C.
A few issues regarding our modeling choices and computation
should be highlighted. First, the distribution for the effect sizes was
assumed normal for computational convenience, although a heavier
tailed distribution could be more robust and often truer to prior
assumptions in GWAS (see, e.g., Park et al. [36]). Double exponential
distribution was used to generate the effect sizes in the simulations,
which may explain the bias to small model sizes in the results
(Figure 3). Yet, the inferences on heritability seem well-calibrated
(Figure 2). However, the normal assumption may be an issue if there
are some variants with large effects and lots of variants with small
effects. Then, the strong associations will increase the variance of the
effect size distribution (via t2), which will affect the implicit threshold
in the spike-and-slab prior to include variants into the model.
Another issue concerns the computation. The local updating
scheme of variant inclusion (c) suffers from large autocorrelations
and may perform poorly if the distribution is multi-modal. Indeed,
there were indications of poormixing between near-by SNPs, but the
calculation of region-wise posterior association probabilities did not
seem to suffer from this. A further analysis of the associated regions
would need to take the potential problems into account.We also note
that our specification of the regions based on the HapMap genetic
maps is simplistic and intended for summarization (similarly, Guan
and Stephens [6] divide the genome into regions based on basepair
positions). That the single-SNP analysis for HDL-C and LDL-C did
not indicate any significant associations not seen in the BMA results
(apart from the few probable false positives addressed in the results),
implies that there at least is no such multi-modality, which would
mask strong associations. However, if multi-modality becomes a
problem, incorporating global moves between tempered chains from
the EvolutionaryMonte Carlo of Bottolo and Richardson [37] to the
current scheme could be of help, albeit with the cost of increased
computational burden. With the settings described in the Results
section, the computation of a single chain for BMA A/AH model
took approximately 96 hours for the HDL-C and LDL-C datasets
(utilizing one core of 2.6 GHz AMD Opteron 2435 CPU). Our
implementation is memory-efficient and allows running multiple
parallel chains, which share the same dataset.
Supporting Information
Text S1 Details of the sampling scheme.
(PDF)
Text S2 PLINK analysis options.
(PDF)
Figure S1 True positive rate as a function of false
positive rate in simulations with all forty replicate
datasets combined within each configuration. sB refers
to Bayesian single-SNP analysis. Regions were defined based on
HapMap genetic maps with 0.005 cM cutoff. sB A and PLINK A
may be difficult to distinguish because of overlap.
(TIF)
Figure S2 True positive rate as a function of false
positive rate in simulations with all forty replicate
datasets combined within each configuration. sB refers
to Bayesian single-SNP analysis. Regions were defined using the
default LD block algorithm in the Haploview software [26]. sB A
and PLINK A may be difficult to distinguish because of overlap.
(TIF)
Figure S3 True positive rate as a function of false
positive rate in simulations with all forty replicate
datasets combined within each configuration. sB refers
to Bayesian single-SNP analysis. Regions were defined based on
HapMap genetic maps with 0.01 cM cutoff (this figure is the same
as in the main article expect for the inclusion of the sB results). sB
A and PLINK A may be difficult to distinguish because of overlap.
(TIF)
Figure S4 Comparison of the posterior association
probabilities between BMA A/AH MCMC chains for
HDL-C and LDL-C (SNP-wise and region-wise with the
regions from HapMap genetic maps with 0.01 cM
cutoff).
(TIF)
Figure S5 Region-wise BMA A posterior association
probabilities for ten permutations of the HDL-C data.
The trait y and the rows of the matrix E were randomly permuted
(both with the same permutation), while the genotypes X were left
to the original order. The same hyperparameters and MCMC
settings were used as with the original dataset.
(TIF)
Figure S6 Estimates of the number of associated
variants in the regions (using HapMap genetic maps
with 0.01 cM cutoff) for HDL-C and LDL-C with BMA A/
AH. Calculated for each region as a sum of the Rao-Blackwellized
posterior association probabilities of the SNPs within the region
[6].
(TIF)
Figure S7 Region-wise BMA A/AH posterior association
probabilities (gray) and PLINK AH ” log10 (p”values)
(green; truncated at 12) for HDL-C and LDL-C.
(TIF)
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